---
layout: default
title: Vecuronium
parent: Model Prediction Only (L5)
nav_order: 354
evidence_level: L5
indication_count: 2
last_modified_at: 2026-10-15
description: "Vecuronium: predicted new indication Insomnia (evidence level L5). Approved use: Not stated in the Philippines registration data (the approved indicat…"
monitor_inn: "Vecuronium"
predicted_indications: ["insomnia (disease)", "irritable bowel syndrome"]
---

# Vecuronium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Vecuronium: From Neuromuscular Blockade to Insomnia
{: .text-alpha }

## One-Sentence Summary

Vecuronium is a non-depolarizing neuromuscular blocker used as a muscle relaxant, typically during anaesthesia and mechanical ventilation. The TxGNN model predicts it may be effective for **insomnia**, but only **1 clinical trial** (an unrelated pharmacokinetic study) and **0 publications** are linked to this prediction. The prediction is a model output without supporting evidence, and the mechanism argues against it.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Philippines registration data (the approved indication field is empty) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| Philippines Market Status | Cancelled only |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available in the data compiled for this report. From general pharmacology, vecuronium is a non-depolarizing neuromuscular blocker. It competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction and causes skeletal muscle paralysis.

**The prediction does not appear to be pharmacologically reasonable.** Vecuronium has no known sedative, hypnotic or central nervous system activity, and it does not cross the blood-brain barrier appreciably. Insomnia is a disorder of sleep initiation or maintenance, and paralysis does not address it. Giving paralysis without sedation could also cause awake paralysis, which would be harmful.

The high score (0.993) most likely reflects a graph-based association artifact, for example shared neighbours among anaesthesia-related and sedative drugs in the knowledge graph. It probably does not reflect a true pharmacological relationship.

The second-ranked prediction, **irritable bowel syndrome** (score 99.11%), is also not mechanistically supported. Vecuronium acts mainly on skeletal muscle and has minimal effect on smooth muscle or autonomic ganglia at clinical doses. It also requires mechanical ventilation, which makes chronic or outpatient use for a functional gastrointestinal disorder impractical. No clinical trials or publications were found for this prediction.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3520 | Observational pharmacokinetic study of understudied drugs given to children as standard of care. Vecuronium is one of many drugs studied. The trial does not evaluate insomnia or any efficacy outcome, so it provides no evidence for this prediction. |

---

## Literature Evidence

Currently no related literature available.

---

## Philippines Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| PNF-0512 | Vecuronium | Not stated | Not stated (registration status: cancelled) |

---

## Safety Considerations

- **Drug Interactions**: The interaction screening found **85 interacting drugs**. The 20 entries reviewed for this report included:
  - **Major**: paromomycin, kanamycin, neomycin (aminoglycoside antibiotics).
  - **Moderate**: magnesium sulfate, magnesium chloride, vancomycin, amphotericin B (including the lipid complex), tetracycline-class antibiotics (doxycycline, tetracycline, minocycline), topical neomycin, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, prednisone), mannitol and metoclopramide.
  - **Minor**: ranitidine.
- **Additional safety concern**: Vecuronium produces skeletal muscle paralysis and requires ventilatory support. Without concurrent sedation, a patient may be paralysed while awake, which makes it unsuitable for a sleep disorder.

For other safety information, please refer to the package insert.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The prediction rests only on a model score. No relevant clinical trials or publications exist, and the evidence level is L5.
- Vecuronium has no sedative or hypnotic activity, so the mechanism does not support its use in insomnia.
- The paralysis it causes is a safety risk in this setting.
- The only Philippines registration is cancelled.

**To proceed, the following is needed:**
- Detailed mechanism-of-action data and the original indication, to support any mechanistic analysis.
- The package insert warnings and contraindications from the Philippines regulator, to allow safety screening.
- Any pharmacological or preclinical rationale for a link to insomnia. Without one, this prediction should be treated as a probable model artifact and deprioritised.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

